Aom0498 (Adamgammadex) received China’s NMPA approval
Aomo Pharma Inc., the U.S. subsidiary of Adamerck, is a biotechnology company founded in 2000 with the mission of developing
Tag: anesthesia
Results of Phase III clinical trial on efficacy and safety of Adamgammadex
This multicentre, randomised, double-blind, positive-controlled, noninferiority phase III clinical trial aimed to investigate the efficacy and safety of adamagammadex compared
A Comparative Study of Sugammadex and Neostigmine: A Bibliometric Analysis of the Past 15 Years
Sugammadex is a novel selective relaxant binding agent for aminosteroid neuromuscular blocking agents (NMBAs). However, existing literature reveals major knowledge
Neostigmine vs. sugammadex: on postoperative nausea and vomiting (PONV) after general anaesthesia
Sugammadex (SGM) is the first cyclodextrin derivative approved as an API, the result of a rational drug design, with a
Comparison of Selective Relaxant Binding Agent Adamgammadex Sodium with Sugammadex for Reversing Rocuronium-Induced Deep Neuromuscular Block
Zhao et al. reported on a phase IIa, single-center, randomized, open-label, and dose-finding study that enrolled 35 patients under general
Improvement of Butamben Anesthetic Efficacy by the Development of Deformable Liposomes Bearing the Drug as Cyclodextrin Complex
This work was aimed at enhancing butamben (BTB) anesthetic efficacy by the “drug-in cyclodextrin (CD)-in deformable liposomes” strategy. In the
The Use of ADV6209 for Premedication in Pediatric Anesthesia
A recently posted phase 2 clinical trial (not yet recruiting) aims to evaluate the effect of ADV6209, a new oral